A study involving women with dense breast tissue found that an abbreviated breast MRI protocol was as effective as the full version in detecting cancer—while taking less than half the time to complete.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.